FibroFind
FibroFind is a UK preclinical CRO that uses proprietary bioreactor technology and precision-cut human tissue slices (PCTS) to deliver human-relevant preclinical testing services — target validation, lead screening, pharmacology, and safety — to global biopharmaceutical sponsors developing drugs for liver, kidney, and lung diseases.
- Company typePrivate
- Founded2018
- HeadquartersGateshead, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
What FibroFind does
FibroFind is a UK-headquartered preclinical contract research organisation (CRO) that provides human-relevant preclinical testing services to global biopharmaceutical and biotech sponsors developing drugs for liver, kidney, and lung diseases. Founded in 2018 in Gateshead by Newcastle University scientists Professors Jelena Mann, Derek Mann, Fiona Oakley, and Dr. Lee Borthwick, the company addresses the well-documented translational gap in drug discovery, where fewer than 10% of drug candidates reach approval, by replacing surrogate preclinical models with evidence generated directly in viable human tissue.
The company's core offering is built on two integrated proprietary assets: a precision-cut tissue slices (PCTS) platform and patented bioreactor technology that together maintain native 3D cellular architecture and functional signalling pathways in ethically procured human liver, lung, and kidney tissue for extended study durations. These assets are delivered through four service modules — Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment — that produce decision-grade data intended to support IND-enabling submissions and to enable earlier go/no-go decisions. Operations are run from a purpose-built laboratory in Gosforth, Newcastle upon Tyne, and supported by advanced liquid handling robotics and AI-assisted data analysis.
FibroFind monetises through project-based professional services contracts under a quote-based pricing model, with revenue tied to bespoke study design and delivery for each biopharma client. The go-to-market is a single enterprise field sales motion targeting global biopharma sponsors directly. Quality, compliance, and data integrity are underpinned by ISO 9001, ISO 14001, Cyber Essentials Plus, GDPR-compliant data handling, and GLP/GxP-aligned scientific frameworks. In May 2025 the business was acquired by private equity firm Vespa Capital to fund its next phase of growth and global expansion, with a strengthened executive team including a CFO, CBO, Chair, and CCO installed alongside the founding scientists.
FibroFind firmographics
Firmographics- Name
- FibroFind
- Legal name
- Fibrofind
- Website
- https://fibrofind.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- FibroFind is a UK preclinical CRO that uses proprietary bioreactor technology and precision-cut human tissue slices (PCTS) to deliver human-relevant preclinical testing services — target validation, lead screening, pharmacology, and safety — to global biopharmaceutical sponsors developing drugs for liver, kidney, and lung diseases.
- Ownership category
- akta.pro rank
FibroFind industry classification
Industry- Product category
- Preclinical Drug Development Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical, Toxicology & Translational Science Staffing FSP (HLAGAOAJ)
Keywords
Where FibroFind is headquartered
LocationHeadquarters
- HQ city
- Gateshead
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
FibroFind business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Preclinical CRO Services: Contract research organization providing expert-led study design, implementation and delivery services to biopharmaceutical companies for drug discovery and development programs. Revenue generated through project-based contracts for testing in human tissue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
FibroFind product offering
Product offeringCore offering
FibroFind provides preclinical drug testing services for biopharmaceutical sponsors by culturing precision-cut slices of viable human liver, lung and kidney tissue inside proprietary bioreactors. Its integrated PCTS platform is used to deliver four service modules (target identification and validation, lead screening and optimization, pharmacology studies, and drug safety assessment) that generate human-relevant preclinical evidence to bridge the translational gap and inform go/no-go decisions.
Product overview
FibroFind is a preclinical CRO operating as a unified platform combining proprietary bioreactor technology with precision-cut tissue slices (PCTS). The core technology consists of the PCTS Platform and Proprietary Bioreactor Technology, which work together to maintain viable human tissue for extended testing. The company offers four integrated service modules: Target Identification and Validation, Lead Screening and Optimization, Pharmacology Studies, and Drug Safety Assessment. This platform-plus-services architecture enables biopharma clients to access human-relevant preclinical testing, replacing simplified cell cultures and animal models with definitive biological data from human liver, lung, and kidney tissue.
Differentiator
Problem solved
Functional benefit
Products and services
- Precision-Cut Tissue Slices (PCTS) Platform
Quantifiable outcome
- Extended study duration without loss of cellular diversity and tissue integrity
- +1 more outcomes
Companies that use FibroFind
Customer profileSegments1 record
Ideal customer profiles1 record
FibroFind technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
FibroFind partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Clinical Partnerships for Tissue ProcurementcoreEstablished clinical partnerships ensuring ethical procurement of viable human liver, lung and kidney tissue for use in PCTS platforms.
- Newcastle UniversitycoreFibroFind was founded by Newcastle University scientists. The company maintains academic partnerships and translational research collaborations. Leadership includes academic, clinical and commercial insight.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
FibroFind competitors and assessment
Company assessmentDirect peers
- Crown Bioscience: Global preclinical CRO offering translational oncology and biospecimen services including patient-derived tissue models. Directly comparable to FibroFind as a translational preclinical CRO selling human-relevant evidence to biopharma, though it is much larger and more oncology-focused.
- Inotiv: Preclinical CRO providing toxicology, safety assessment, and research models to biopharma. Closely comparable to FibroFind as a preclinical CRO serving biopharma sponsors, though Inotiv's core is animal-model toxicology rather than ex-vivo human tissue.
- AnaBios: Specialist in human tissue-based preclinical research, leveraging ethically sourced human tissues for drug discovery and safety assessment. Highly comparable to FibroFind given its use of viable human tissue for preclinical drug development services to biopharma.
- Reaction Biology: Preclinical CRO offering a broad range of drug discovery services including target-based screening, biophysics, and safety pharmacology. Comparable to FibroFind as a smaller-scale preclinical CRO serving biopharma, though without the proprietary human-tissue platform.
- Cyprotex (an Evotec company): Preclinical ADME/DMPK and safety/toxicology CRO serving biopharma, now part of Evotec. Comparable to FibroFind as a specialized preclinical services provider focused on derisking drug candidates before clinical development, though focused on in-vitro and in-silico ADME rather than human tissue slices.
Broad incumbents
- Charles River Laboratories: One of the largest global preclinical CROs offering safety assessment, discovery, and manufacturing services to biopharma. Comparable to FibroFind as a destination for outsourced preclinical drug development, though FibroFind's tissue-slice platform is a much narrower niche.
- Eurofins Scientific: Global testing services group with substantial pharma and biopharma testing capabilities including preclinical and central laboratory services. Overlaps with FibroFind as a provider of laboratory-based drug development evidence to biopharma sponsors, but operates at vastly greater scale and breadth.
- Evotec: Global drug discovery and development CRO with deep preclinical and translational science capabilities, including the Cyprotex safety/toxicology franchise. Comparable to FibroFind in addressing the translational gap for biopharma R&D, though Evotec operates across the full drug discovery value chain rather than just tissue-based preclinical.
- WuXi AppTec: Global CRO/CDMO with extensive preclinical drug development services across discovery, toxicology, and bioanalysis. Overlaps with FibroFind as a comprehensive preclinical service provider to biopharma, though at materially larger scale and broader scope.
Emerging players
- InSphero: Provider of 3D microtissue (organoid) models for drug discovery and safety testing. Comparable to FibroFind as an emerging human-relevant preclinical platform aiming to replace animal models, though focused on organoid microtissues rather than precision-cut tissue slices.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
FibroFind social profiles
Digital presenceFibroFind compliance and trust
Trust signalCompliance5 records
FibroFind financial estimates
Financial estimateRevenue estimate
Valuation estimate
FibroFind leadership team
Management profileNumber of profiles
Profiles10 records
FibroFind funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FibroFind M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FibroFind
What does FibroFind do?
FibroFind provides preclinical drug testing services for biopharmaceutical sponsors by culturing precision-cut slices of viable human liver, lung and kidney tissue inside proprietary bioreactors. Its integrated PCTS platform is used to deliver four service modules (target identification and validation, lead screening and optimization, pharmacology studies, and drug safety assessment) that generate human-relevant preclinical evidence to bridge the translational gap and inform go/no-go decisions.
Is FibroFind a public or private company?
FibroFind is a private company. It is classified as private equity controlled and is currently operating.
When was FibroFind founded?
FibroFind was founded in 2018. It employs 1 to 10 people.
Where is FibroFind based?
FibroFind is headquartered in Gateshead, United Kingdom, in the Europe region.
How does FibroFind make money?
One revenue line is on record: preclinical CRO Services.
Who are FibroFind's main competitors?
Direct peers on record are Crown Bioscience, Inotiv, AnaBios, Reaction Biology and Cyprotex (an Evotec company). Broad incumbents are Charles River Laboratories, Eurofins Scientific, Evotec and WuXi AppTec. InSphero is listed as an emerging player.
Does FibroFind have an API?
No public API is recorded for FibroFind.
What industry is FibroFind in?
FibroFind's product category is Preclinical Drug Development Services. Its primary akta.pro industry code is HLAGAOAJ, Preclinical, Toxicology & Translational Science Staffing FSP. Its NAICS code is 62151 and its SIC code is 8071.